0001355250-12-000015.txt : 20120420 0001355250-12-000015.hdr.sgml : 20120420 20120420083714 ACCESSION NUMBER: 0001355250-12-000015 CONFORMED SUBMISSION TYPE: 8-K PUBLIC DOCUMENT COUNT: 1 CONFORMED PERIOD OF REPORT: 20120419 ITEM INFORMATION: Other Events FILED AS OF DATE: 20120420 DATE AS OF CHANGE: 20120420 FILER: COMPANY DATA: COMPANY CONFORMED NAME: Cellceutix CORP CENTRAL INDEX KEY: 0001355250 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] IRS NUMBER: 134303398 STATE OF INCORPORATION: NV FISCAL YEAR END: 0630 FILING VALUES: FORM TYPE: 8-K SEC ACT: 1934 Act SEC FILE NUMBER: 000-52321 FILM NUMBER: 12769598 BUSINESS ADDRESS: STREET 1: 100 CUMMING CENTER STREET 2: SUITE 151-B CITY: BEVERLY STATE: MA ZIP: 01915 BUSINESS PHONE: (978)-633-3623 MAIL ADDRESS: STREET 1: 100 CUMMING CENTER STREET 2: SUITE 151-B CITY: BEVERLY STATE: MA ZIP: 01915 FORMER COMPANY: FORMER CONFORMED NAME: EconoShare, Inc. DATE OF NAME CHANGE: 20060306 8-K 1 f419128klivformatech.htm Converted by EDGARwiz

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

 

FORM 8-K

 

CURRENT REPORT

Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934

 

Date of Report April 20,  2012

(Date of earliest event reported: April 19, 2012)

 

CELLCEUTIX CORPORATION

 

  


 

 

Nevada

 

30-0565645

 

 

 

(State or Other Jurisdiction of

 

(I.R.S. Employer

Incorporation or Organization)

 

Identification Number)

 

 

100 Cumming Center, Suite 151-B

Beverly, MA  01915

 

 

 

 (Address of principal executive offices and zip code)

 

(978)-633-3623

(Registrant's telephone number, including area code) 

 

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):

 

o

 

Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

 

 

 

o

 

Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

 

 

 

o

 

Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

 

 

 

o

 

Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

 

 

   

Item 8.01 Other Events

 


In April 2012, Cellceutix was advised that the Bankruptcy Court Trustee for Formatech, Inc. had filed a notice of intended sale of 184,375 shares of non-registered restricted common shares of Cellceutix held by Formatech.  Cellceutix is filing an objection to this sale with the United States Bankruptcy Court.  Cellceutix believes these



shares were not earned by Formatech and were received by Formatech under  fraudulent pretense. Consequently we are requesting the return of the shares to Cellceutix.

 

 

SIGNATURES

 

 

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

 

Date:  April 20, 2012

 

 

 

 

 

 

CELLCEUTIX CORPORATION

 

 

 

 

 

 

 

 

By:  

/s/ Leo Ehrlich

 

 

 

Chief Executive Officer